Transforming Pharma with Smart Platforms: Digital Trials, Predictive Insights and Scalable Care

Abstract

Clinical trials remain the costliest and slowest stage of drug development, with average costs exceeding USD 2 billion per approved drug and timelines often surpassing a decade. Recruitment inefficiencies, high dropout rates, and limited diagnostic integration exacerbate this burden. While decentralized clinical trials (DCTs) promise to reduce patient burden and broaden access, most remain fragmented, with wearables, apps, and telemedicine solutions operating in silos.

This paper introduces LifeLens™, an AI-enabled multimodal diagnostic device embedded in the CloudHub Smart Clinical Trial Platform. LifeLens unifies diagnostics across oncology, ophthalmology, and dermatology. Using lung cancer as a representative example, LifeLens enables a diagnostic continuum: symptom triage → lung auscultation → CT/X-ray AI analysis → histopathology confirmation. Additional modules support diabetic retinopathy (DR) screening via fundus imaging and dermatology detection of >50 skin conditions.

Our evaluations demonstrate that LifeLens and the broader CloudHub ecosystem can:

• Reduce trial operational costs by 30–40%,
• Accelerate recruitment by 30–50%,
• Shorten time-to-market by 6–12 months
• Improve patient retention to >90%.

We conclude that multimodal, AI-driven diagnostic platforms represent the foundation of DCT 2.0, enabling unified diagnostics, predictive insights, compliance automation, and equitable global access.